BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

468 related articles for article (PubMed ID: 10163432)

  • 1. The UK pharmaceutical market. An overview.
    Towse A
    Pharmacoeconomics; 1996; 10 Suppl 2():14-25. PubMed ID: 10163432
    [TBL] [Abstract][Full Text] [Related]  

  • 2. European healthcare policies for controlling drug expenditure.
    Ess SM; Schneeweiss S; Szucs TD
    Pharmacoeconomics; 2003; 21(2):89-103. PubMed ID: 12515571
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New medicines in primary care: a review of influences on general practitioner prescribing.
    Mason A
    J Clin Pharm Ther; 2008 Feb; 33(1):1-10. PubMed ID: 18211610
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Straight talk with... Mark Sculpher. Interview by Kate Ravilious.
    Sculpher M
    Nat Med; 2012 Sep; 18(9):1315. PubMed ID: 22961148
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmaceutical expenditure and therapeutic value of new medicines in Spain.
    Darba J
    Pharmacoeconomics; 2003; 21(16):1211-2. PubMed ID: 14594440
    [No Abstract]   [Full Text] [Related]  

  • 6. The new pharmaceutical policy in Italy.
    Fattore G; Jommi C
    Health Policy; 1998 Oct; 46(1):21-41. PubMed ID: 10187653
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Drug pricing and reimbursement in France. Towards a new model?
    Le Pen C
    Pharmacoeconomics; 1996; 10 Suppl 2():26-36. PubMed ID: 10163433
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Time to fix the price fix.
    Earl-Slater A
    Health Serv J; 1997 Nov; 107(5578):22-3. PubMed ID: 10174008
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Projecting expenditure on medicines in the UK NHS.
    O'Neill P; Mestre-Ferrandiz J; Puig-Peiro R; Sussex J
    Pharmacoeconomics; 2013 Oct; 31(10):933-57. PubMed ID: 24037786
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmaceutical expenditure in Spain: cost and control.
    Lopez Bastida J; Mossialos E
    Int J Health Serv; 2000; 30(3):597-616. PubMed ID: 11109184
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Influence of patient co-payments on atypical antipsychotic choice in Poland: implications once generic atypicals are available.
    Wladysiuk M; Araszkiewicz A; Godman B; Szabert K; Barbui C; Haycox A
    Appl Health Econ Health Policy; 2011 Mar; 9(2):101-10. PubMed ID: 21271749
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Regulating pharmaceutical markets: improving efficiency and controlling costs in the UK.
    Walley T; Mrazek M; Mossialos E
    Int J Health Plann Manage; 2005; 20(4):375-98. PubMed ID: 16335083
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The management of the cost and utilisation of pharmaceuticals in the United Kingdom.
    Burstall ML
    Health Policy; 1997 Sep; 41 Suppl():S27-43. PubMed ID: 10174472
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Experts' agency problems: evidence from the prescription drug market in Japan.
    Iizuka T
    Rand J Econ; 2007; 38(3):844-62. PubMed ID: 18478669
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The UK indicative prescribing scheme: background and operation.
    Bligh J; Walley T
    Pharmacoeconomics; 1992 Aug; 2(2):137-52. PubMed ID: 10146953
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Historical overview of regulatory framework development on pricing and reimbursement of medicines in Bulgaria.
    Vassileva M; Kamusheva M; Manova M; Savova A; Tachkov K; Petrova G
    Expert Rev Pharmacoecon Outcomes Res; 2019 Dec; 19(6):733-742. PubMed ID: 30900482
    [No Abstract]   [Full Text] [Related]  

  • 17. A qualitative study of GPs' and PCO stakeholders' views on the importance and influence of cost on prescribing.
    Prosser H; Walley T
    Soc Sci Med; 2005 Mar; 60(6):1335-46. PubMed ID: 15626528
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Analysis of the Italian generic medicines retail market: recommendations to enhance long-term sustainability.
    Dylst P; Vulto A; Simoens S
    Expert Rev Pharmacoecon Outcomes Res; 2015 Feb; 15(1):33-42. PubMed ID: 25138241
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pricing of prescription drugs and its impact on physicians' choice behavior.
    Miao-Sheng C; Yu-Ti S
    Health Care Manag Sci; 2008 Sep; 11(3):288-95. PubMed ID: 18826006
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Developing competitive and sustainable Polish generic medicines market.
    Simoens S
    Croat Med J; 2009 Oct; 50(5):440-8. PubMed ID: 19839067
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.